Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASXC Asensus Surgical	$0.35	$0.35	$0.17 ▼ $0.40	$94.74M	1.37	2.03 million shs	N/A
BFLY Butterfly Network	$1.59 +2.3%	$1.75	$0.93 ▼ $4.98	$390.20M	2.45	3.80 million shs	6.03 million shs
DCTH Delcath Systems	$11.12 +2.1%	$11.70	$8.08 ▼ $18.23	$380.95M	0.82	849,254 shs	359,826 shs
RXST RxSight	$8.50 -1.3%	$9.52	$6.32 ▼ $57.53	$352.29M	1.16	1.18 million shs	1.61 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASXC Asensus Surgical	0.00%	0.00%	0.00%	0.00%	+4.32%
BFLY Butterfly Network	+1.97%	+7.99%	-20.87%	-39.02%	+62.08%
DCTH Delcath Systems	-2.07%	+2.25%	-4.56%	-33.64%	+35.96%
RXST RxSight	-7.22%	+1.41%	+8.03%	-46.22%	-84.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASXC Asensus Surgical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BFLY Butterfly Network	2.7587 of 5 stars	3.4	3.0	0.0	0.0	2.0	2.5	0.6
DCTH Delcath Systems	2.6077 of 5 stars	3.5	2.0	0.0	0.0	2.2	2.5	0.6
RXST RxSight	1.6403 of 5 stars	3.0	1.0	0.0	0.0	2.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASXC Asensus Surgical	0.00	N/A	N/A	N/A
BFLY Butterfly Network	2.75	Moderate Buy	$3.00	89.27% Upside
DCTH Delcath Systems	3.00	Buy	$24.50	120.32% Upside
RXST RxSight	1.91	Reduce	$10.00	17.65% Upside

Current Analyst Ratings Breakdown

Latest ASXC, DCTH, RXST, and BFLY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	RXST RxSight	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $8.00
8/8/2025	RXST RxSight	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$9.00 ➝ $8.00
8/8/2025	RXST RxSight	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $11.00
8/7/2025	DCTH Delcath Systems	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$29.00 ➝ $31.00
8/4/2025	BFLY Butterfly Network	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Positive ➝ Positive	$2.00
8/1/2025	BFLY Butterfly Network	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/15/2025	RXST RxSight	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$20.00 ➝ $9.00
7/10/2025	RXST RxSight	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$24.00 ➝ $9.00
7/9/2025	RXST RxSight	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$18.00 ➝ $9.00
7/9/2025	RXST RxSight	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$18.00 ➝ $10.00
7/9/2025	RXST RxSight	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$17.00 ➝ $9.00

(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASXC Asensus Surgical	$8.58M	11.04	N/A	N/A	$0.13 per share	2.68
BFLY Butterfly Network	$82.06M	4.86	N/A	N/A	$0.92 per share	1.72
DCTH Delcath Systems	$37.21M	10.45	N/A	N/A	$3.00 per share	3.71
RXST RxSight	$139.93M	2.49	N/A	N/A	$6.79 per share	1.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASXC Asensus Surgical	-$78.43M	-$0.31	N/A	N/A	N/A	-902.25%	-184.10%	-114.75%	N/A
BFLY Butterfly Network	-$72.49M	-$0.28	N/A	N/A	N/A	-71.79%	-30.53%	-21.80%	11/7/2025 (Estimated)
DCTH Delcath Systems	-$26.39M	$0.05	222.40	N/A	N/A	3.18%	6.91%	5.80%	11/14/2025 (Estimated)
RXST RxSight	-$27.45M	-$0.80	N/A	N/A	N/A	-21.93%	-11.56%	-10.31%	11/6/2025 (Estimated)

Latest ASXC, DCTH, RXST, and BFLY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Guidance Update	RXST RxSight	-$0.04	-$0.08	-$0.04	-$0.29	$39.78 million	$33.64 million
8/6/2025	Q2 2025	DCTH Delcath Systems	$0.02	$0.07	+$0.05	$0.07	$22.84 million	$24.16 million
8/1/2025	Q2 2025	BFLY Butterfly Network	-$0.07	-$0.06	+$0.01	-$0.06	$23.91 million	$23.38 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASXC Asensus Surgical	N/A	N/A	N/A	N/A	N/A
BFLY Butterfly Network	N/A	N/A	N/A	N/A	N/A
DCTH Delcath Systems	N/A	N/A	N/A	N/A	N/A
RXST RxSight	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASXC Asensus Surgical	N/A	1.00	0.69
BFLY Butterfly Network	N/A	5.68	4.14
DCTH Delcath Systems	N/A	10.88	9.87
RXST RxSight	N/A	13.93	12.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASXC Asensus Surgical	9.35%
BFLY Butterfly Network	37.85%
DCTH Delcath Systems	61.12%
RXST RxSight	78.78%

Insider Ownership

Company	Insider Ownership
ASXC Asensus Surgical	2.87%
BFLY Butterfly Network	25.18%
DCTH Delcath Systems	17.94%
RXST RxSight	9.57%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASXC Asensus Surgical	170	272.33 million	264.52 million	Not Optionable
BFLY Butterfly Network	460	251.74 million	188.35 million	Optionable
DCTH Delcath Systems	60	34.98 million	28.71 million	Optionable
RXST RxSight	220	40.92 million	37.00 million	Optionable

ASXC, DCTH, RXST, and BFLY Headlines

Recent News About These Companies

INVESTOR ALERT: Berger Montague Advises RxSight, Inc. (NASDAQ: RXST) Investors to Inquire About a Securities Fraud Class Action by September 22, 2025

5 hours ago | prnewswire.com

Lost Money on RxSight, Inc.(RXST)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

August 26 at 8:46 AM | prnewswire.com

Investors in RxSight, Inc. Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights – RXST

August 25 at 5:51 PM | globenewswire.com

RxSight, Inc. to Present at the Morgan Stanley Healthcare Conference

August 25 at 4:05 PM | globenewswire.com

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages RxSight, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RXST

August 25 at 1:18 PM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in RxSight, Inc. of Class Action Lawsuit and Upcoming Deadlines - RXST

August 25 at 10:48 AM | globenewswire.com

Doheny Asset Management CA Raises Stock Holdings in RxSight, Inc. $RXST

August 25 at 8:56 AM | marketbeat.com

RXST STOCK ALERT: RxSight, Inc. Investors may have been Affected by Fraud -- Contact BFA Law by September 22 about the Class Action (NASDAQ:RXST)

August 25 at 8:46 AM | globenewswire.com

The Gross Law Firm Reminds RxSight, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - RXST

August 25 at 8:45 AM | prnewswire.com

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against RxSight, Inc. (NASDAQ: RXST)

August 25 at 8:21 AM | globenewswire.com

ROSEN, NATIONAL TRIAL COUNSEL, Encourages RxSight, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RXST

August 24 at 9:10 AM | markets.businessinsider.com

RxSight, Inc. $RXST Shares Bought by Quantbot Technologies LP

August 24 at 5:16 AM | marketbeat.com

RXST CLASS REMINDER: Suffer Losses on Your RxSight, Inc. Investment? Contact BFA Law before the September 22 Court Deadline (NASDAQ:RXST)

August 23 at 7:08 AM | globenewswire.com

ROSEN, SKILLED INVESTOR COUNSEL, Encourages RxSight, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RXST

August 22, 2025 | globenewswire.com

Lost Money on RxSight, Inc.(RXST)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

August 22, 2025 | globenewswire.com

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight

August 22, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in RxSight, Inc. of Class Action Lawsuit and Upcoming Deadlines - RXST

August 22, 2025 | prnewswire.com

RxSight, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - RXST

August 22, 2025 | prnewswire.com

Credit Agricole S A Has $19.85 Million Position in RxSight, Inc. $RXST

August 22, 2025 | marketbeat.com

Algert Global LLC Has $3.51 Million Stock Position in RxSight, Inc. $RXST

August 22, 2025 | marketbeat.com

RXST Investors Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit

August 21, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASXC, DCTH, RXST, and BFLY Company Descriptions

Asensus Surgical NYSEAMERICAN:ASXC

$0.35 0.00 (0.00%)

As of 08/22/2024

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.

Butterfly Network NYSE:BFLY

$1.58 +0.04 (+2.26%)

Closing price 03:59 PM Eastern

Extended Trading

$1.62 +0.04 (+2.21%)

As of 07:59 PM Eastern

Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging in a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; and Butterfly iQ+ Vet, a handheld ultrasound system designed for veterinarians. The company also provides Butterfly system, which includes probes, and related accessories and software subscriptions to healthcare systems, physicians, and healthcare providers through a direct sales force, distributors, and eCommerce channel. In addition, it offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software, as well as professional services for large scale deployments; and ScanLab, an education-only app provides written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.

Delcath Systems NASDAQ:DCTH

$11.12 +0.23 (+2.11%)

Closing price 04:00 PM Eastern

Extended Trading

$11.10 -0.01 (-0.13%)

As of 07:36 PM Eastern

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

RxSight NASDAQ:RXST

$8.50 -0.11 (-1.28%)

Closing price 04:00 PM Eastern

Extended Trading

$8.49 -0.01 (-0.07%)

As of 07:28 PM Eastern

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time